Aurora (TSX:ACB) CEO Foresees Major Marijuana Stock Carnage in 2020

With the company’s CEO predicting “carnage” for marijuana stocks in 2020, investors should avoid taking a position on Aurora Cannabis stock for now.

| More on:

Cannabis stocks are the fallen stars in 2019. Investors are losing interest in cannabis companies because of their mounting losses, controversies, and scandals. Since April, the market values of big and small players are dropping significantly. The key to regaining the trust of investors is for the marijuana stocks to show profitability.

According to Terry Booth, CEO of Aurora Cannabis (TSX:ACB)(NYSE:ACB), the turbulence is not over, and carnage is looming over the next year. Booth is not worrying about the demand for cannabis. He sees the need for producers to reduce production costs in a market beset by oversupply.

Constant disappointment

Sadly, marijuana investments have been a continual disappointment for investors. It appears that marijuana companies, including Aurora, are presenting ambitious guidance. Instead of delivering, Aurora is burning cash and diluting equity. As a result, the stock is suffering.

As of this writing, Aurora’s market capitalization is down to $3.42 billion from $7.63 billion in late August. Similarly, the price has fallen to $3.26 per share. On a year-to-date basis, Aurora is down 52%.

Last month, the company was able to secure a US$400 million at-the-market equity financing program. Booth said the funding would allow this top cannabis producer to handle its operations during the current downtrend.

The high cost of production ($4-$5 per gram) is hurting other cannabis companies. In the coming months, the carnage in the production area will no longer be tolerable. Aurora can withstand the effect, as it is a low-cost player. It’s producing cannabis at less than $1. But Aurora will not get into a price war.

However, in case of a price war due to oversupply, the company is best prepared to deal with it. To show good faith and counter the negative impression, Booth bought 270,000 worth of Aurora shares (nearly $1 million) in late November.

Industry outlook

Aurora’s CEO summarized the industry situation today. Booth said, “Remember, they used to value our companies based on the size of our vault and then based it on the size of our licence, and then they based on the funding capacity and they’re finally moving towards can these guys make money.”

Aurora’s September quarterly report was horrendous. Likewise, with the sizeable convertible debt falling due on March 9, 2020, the company decided for all debtholders to convert into common shares. While the dilution was painful to shareholders, it was the only way Aurora can attract new investors.

The net effect of this convertible debt conversion is a reduction of the market cap to $2.6 billion, with the stock price settling at $2.50 per share. Fortunately, with $153 million in cash as of the quarter ended September 30, 2019, plus the US$400 million funding, Aurora can cover capital-spending plans in 2019.

Precarious state

The ongoing dilution at Aurora is a deal buster to would-be investors. However, the conversion of its debentures in 2020 as well the $190 million reductions in capital spending will improve the company’s liquidity position.

Aurora is making canny moves to ensure a bright long-term future and maintain its industry-leading position. For investors, fasten your seat belts and adopt a wait-and-see attitude. The ride is going to be turbulent in 2020.

Fool contributor Christopher Liew has no position in any of the stocks mentioned.

More on Cannabis Stocks

four people hold happy emoji masks
Dividend Stocks

Wary of Mining Companies? A Lower-Risk Way to Get in on the Gold and Silver Surge

Frenco-Nevada (TSX:FNV) stock might be a wiser way to play the run in gold prices this year.

Read more »

Cannabis smoke
Cannabis Stocks

Have Cannabis Stocks Totally Gone Up in Smoke?

Let's dive into whether Canadian cannabis stocks are still investable, and what investors should make of the recent volatility in…

Read more »

Researcher works in hemp field
Cannabis Stocks

1 Undervalued Cannabis Stock to Buy and Hold Over the Next Decade

Green Thumb is a beaten-down cannabis stock that trades at a compelling valuation in September 2025.

Read more »

Researcher works in hemp field
Cannabis Stocks

Pot Stocks Rallied Hard in August: Is There More to Come?

Tilray Brands (TSX:TLRY) and the broad basket of pot stocks could heat up from here.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Stock Jumped 30% Last Month: What’s Going on?

Canopy Growth (TSX:WEED) stock is picking up traction again, making it an enticing weed play to buy on strength.

Read more »

A cannabis plant grows.
Cannabis Stocks

These Threats Facing Canopy Growth Stock Could Justify Selling it

Let's dive into whether Canopy Growth (TSX:WEED) is a top stock investors should buy right now after its recent dip…

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

This BioCannabis Firm Could Explode with Product Approval

This cannabis stock used to be a major name, so where does it stand now?

Read more »

Medicinal research is conducted on cannabis.
Stocks for Beginners

This TSX Health-Care Stock Is a Long-Term Buy for Patient Investors

This TSX stock continues to be one of the best long-term opportunities, if you're patient.

Read more »